Bayer Schering Pharma’s first Phase II trial with oral agent Riociguat (BAY 63-2521) in pulmonary hypertension, owing to interstitial lung disease (PH-ILD), has successfully been completed. The primary
Celgene UK has announced that preliminary clinical data from a phase III, randomized, double-blind study of elderly patients newly diagnosed with multiple myeloma, were presented during the 51st
New data published by Schering-Plough this week in the Primary Care Respiratory Journal (PCRJ) showed that allergic rhinitis quadruples the likelihood of asthma patients having poor control over
Roche Molecular Systems (Roche) has launched new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas 4800
Ranbaxy will be launching a generic version of Astellas’ Flomax urinary drug in March 2010. The news was reported by the chief financial officer on Thursday, stated Reuters.
CyDex Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) has issued a patent to the company entitled ‘Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation
India-based Biocon and HCG group of Hospitals have announced their partnership to conduct a study to evaluate the potential benefits of BIOMAb EGFR in cervical cancer patients. The
Findings from a newly released study by KMR Group found that the time it takes to get a site contract approved is five to six weeks on average.
Lotus Pharmaceuticals (Lotus) has reported that Liang Fang, a controlled operating entity of Lotus has appointed Jinzhong Han as a general manager of the company’s over-the-counter drug division
Access has provided an update on the European commercial launch of its MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.